Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03292003 · ClinicalTrials.gov registry record

Journey II Bi-Cruciate Stabilized (BCS) Total Knee System Retrospective Study

A clinical trial of Total Knee Arthroplasty, sponsored by Smith & Nephew.

Completed
Registry status
1,694
Enrollment target
12
Study locations

NCT03292003: Completed study of Total Knee Arthroplasty, sponsored by Smith & Nephew.

NCT03292003 is a study of Total Knee Arthroplasty that has completed, run by Smith & Nephew. The registered enrollment target is 1,694 participants, above the 237-participant average among 29 other Total Knee Arthroplasty trials with a reported enrollment target (615% higher). The trial reports 12 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03292003, a study of Total Knee Arthroplasty, has completed, sponsored by Smith & Nephew.

COMPLETED
Registry status
1,694 participants
Enrollment target
12
Study locations

Study Summary

The objective of this study is to estimate the safety and performance of Journey II BCS TKS.

Primary Outcome

Number of revisions

Conditions Studied

Interventions

  • DEVICE Journey II BCS Total Knee System

Study Locations (12)

Other

  • Jesse Ziekenhuis - Hasselt
  • UZ Leuven Campus - Pellenberg
  • Christen Ortho AG - Bern

Colorado

  • University of Colorado Orthopaedics - Aurora

Florida

  • Andrews Research and Education Foundation - Gulf Breeze

Indiana

  • Methodist Sports Medicine - Indianapolis

New York

  • Hospital for Special Surgery - New York

Pennsylvania

  • University Orthopaedics Center - State College

Tennessee

  • TN Orthopaedic Foundation for Education and Research - Knoxville

Texas

  • San Antonio Orthopaedic Specialists - San Antonio

Trial Details

FieldValue
Enrollment Target 1,694 participants
Start Date 2016-12-30
Est. Completion 2018-09-24
Smith & Nephew

72 total trials

What the finished NCT03292003 record still lists

NCT03292003 is an observational study that tracks outcomes without assigning an intervention. Its 1,694 participants enrollment target places it among the larger protocols in the corpus, above the 237-participant average among 29 other Total Knee Arthroplasty trials with a reported enrollment target (615% higher).

The record links to 1 condition, with Total Knee Arthroplasty appearing as the primary indexed condition, and to 1 intervention - of which Journey II BCS Total Knee System is the first listed.

NCT03292003 lists 12 locations in 10 states (Other, Colorado, Florida).

Frequently Asked Questions

What is clinical trial NCT03292003 about?

NCT03292003 is a clinical study titled "Journey II Bi-Cruciate Stabilized (BCS) Total Knee System Retrospective Study". The objective of this study is to estimate the safety and performance of Journey II BCS TKS.

What is the current status of trial NCT03292003?

This trial is currently completed. The enrollment target is 1,694 participants. The study started on 2016-12-30. Estimated completion is 2018-09-24.

What conditions does trial NCT03292003 study?

This clinical trial studies the following conditions: Total Knee Arthroplasty.

What interventions are being tested in trial NCT03292003?

The interventions under investigation include: Journey II BCS Total Knee System (DEVICE).

Who is sponsoring clinical trial NCT03292003?

This trial is sponsored by Smith & Nephew, which has 72 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03292003 being conducted?

This trial has 12 study locations across Colorado, Florida, Indiana, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Total Knee Arthroplasty

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03292003's enrollment target sits among peer trials

1,694 2nd of 29 the highest of 29 other Total Knee Arthroplasty trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Total Knee Arthroplasty trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04321200 · 1,700 participants

    PANDA Gym: Automated Assessment of Neurodevelopment in Infants at Risk for Motor Disability

  • NCT06238622 · 1,700 participants · Phase 3

    A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

  • NCT07284901 · 1,700 participants · Phase 3

    Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

  • NCT07304531 · 1,705 participants

    First To Know Pregnancy Test - Clinical Evaluation Protocol

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03292003, the US trial registry maintained by the National Library of Medicine. NCT03292003 (large enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.